Progression-free survival. Kaplan-Meier curves showing progression-free survival in the overall cohort (A), the antibody-drug conjugate (ADC)-exposed patients (B), and the BsAb-exposed patients (C). ^†Classification is based on the last anti-BCMA therapy used if patients received >1 therapy.